Samsung Biologics has been included in the Dow Jones Best-in-Class World Index for the fifth consecutive year, reflecting its strong commitment to environmental, social, and governance (ESG) practices. The recognition is based on a rigorous global sustainability assessment and highlights the company's improvements in supply chain management, environmental care, and workplace safety. This continued inclusion underscores Samsung Biologics' proactive approach to sustainable growth and transparent governance, supported by recent accolades like an EcoVadis Platinum rating and a sustainability award. The company plans to keep advancing its ESG initiatives while expanding its global manufacturing capacity to support future therapies.
The Rosen Law Firm is investigating a class action lawsuit on behalf of Barclays PLC shareholders following reports that Barclays had significant exposure to a collapsed UK mortgage lender, Market Financial Solutions Ltd (MFS). The news caused Barcla...
WEMIX, a South Korean blockchain gaming platform, is investigating a potential security breach involving the ownership of its USDC-backed stablecoin contract, WEMIX$. This comes months after a major hack in February 2025 that drained $6.1 million wor...
XRP remains range-bound near $1.10 amid slowing spot ETF inflows, which are seen as key to breaking its two-month trading range. Despite positive developments like Mastercard's AI payment integration, Ripple Mint platform launch, and EU regulatory ap...
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
This week, U.S. markets focus on the Federal Reserve's July meeting, key inflation data like Core PCE, and second-quarter GDP figures, alongside major tech earnings from Microsoft, Meta, Apple, and Amazon. Rising oil prices and geopolitical tensions ...
